Mepha

Mepha is a well-established, Swiss-based generic drug manufacturer and a key subsidiary of the global generics giant Teva. Operating for over 75 years, it leverages Teva's global scale and R&D while maintaining a strong local presence and reputation for quality in the Swiss and European markets. Its business model centers on providing affordable, bioequivalent alternatives to off-patent originator drugs across a broad range of therapeutic areas. As part of Teva, its strategic value lies in regional manufacturing, portfolio depth, and navigating the complex European generic drug reimbursement landscape.

Generic drug development and manufacturing platform focused on formulation science, bioequivalence studies, and complex generic product development, leveraging Teva's global R&D and supply chain infrastructure.

Mepha, as part of Teva, competes in a highly fragmented global generics market against other large players like Sandoz (Novartis), Viatris, and Fresenius Kabi, as well as numerous regional and local manufacturers. Competition is primarily on price, portfolio breadth, and supply reliability.